BioProcess International | Dan Stanton | May 14, 2019
For its first quarter 2019, Pfenex reported a 177% jump in revenues year-on-year to $10.4 million (€9.2 million), attributed to milestone payments and recognition of deferred revenues from its PF708 partners, and increased sales of its CRM197 product.
Pfenex Case Study
Read this case study before selecting keyhole limpet hemocyanin (KLH) as your preferred carrier protein. Our client measured higher antibody titers by ELISA and stronger neutralizing capacities for CRM197.
Pfenex Case Study
Pfenex CRM197 can be supplied in kilogram scale to meet any commercial vaccine need. When contrasting carrier proteins, Pfenex CRM197 is the option that has been validated by positive Phase 3 results, and is sustainably sourced.
Pfenex Press Release
SAN DIEGO, March 6, 2019—Pfenex Inc. (NYSE American: PFNX) today announced that Serum Institute of India Private Limited (SIIPL), has completed a pivotal Phase 3 study for Pneumosil® a 10-valent pneumococcal conjugate vaccine, in which Serum Institute indicates all primary and secondary objectives were met.
Pfenex Press Release
SAN DIEGO July 12, 2018 — Pfenex Inc. (NYSE AMERICAN: PFNX) today announced the receipt of a milestone payment from Merck associated with the initiation of the first Phase 3 clinical study of (V114), an investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease.
ScienceDirect.com | By: John M. Hickey, et al. | July 2018
PATH funded research determines Pfenex CRM197 has higher overall purity than 4 other CRM197 samples from both E. coli and C. diphtheria expression.
in-Pharma Technologist | By: Dan Stanton | January 21, 2013
Pfenex can support large volume annual demand for CRM197 with its vertically integrated offering and purpose built, state of the art cGMP manufacturing facility.
Genetic Engineering & Biotechnology News | January 16, 2013
Did you know Pfenex has been manufacturing large volumes of cGMP CRM197 since 2012 supporting a broad range of products from preclinical through to registration. You won’t find a competing CRM197 product with a more extensive clinical and regulatory experience.
Genetic Engineering & Biotechnology News | December 1, 2012
Excerpt: Within the rapidly growing vaccine space, conjugate vaccines—polysaccharide antigens covalently linked to carrier proteins—have been shown to be effective against several bacterial pathogens.
BioProcess International | Cassidy Brady, Kevin Killeen, William Taylor and Anant Patkar | November 1, 2012
Why choose Pfenex CRM197? Continuity of supply is just one reason highlighted in this article.
